Abstract: The present invention provides a therapeutic agent for an immune/inflammatory disease comprising an anti-human TIGIT antibody, which activates a suppressive immune checkpoint molecule (TIGIT), as an active ingredient. Also, provided is an antibody having the following characteristics a) and b): a) the third CDR of heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 4 b) the third CDR of light chain variable region comprises the amino acid sequence of SEQ ID NO: 6.

Abstract: Provided is a T cell receptor containing, as ? chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 1 to 3, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 4 to 6, as ? chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 7 to 9, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 10 to 12, and capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 27 or a complex of the peptide and HLA-A24.

Abstract: Provided is a T cell receptor capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 27 or a complex of the peptide and HLA-A24. A T cell receptor capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 28 or a complex of the peptide and HLA-A02. Disclosed T cell receptors are useful in treating or avoiding cancers which are associated with expression of glypican-3.

Abstract: The present invention provides a system for providing a T cell product, including a T cell master cell bank and/or a T cell working cell bank.

Abstract: Disclosed is a method for detecting regulatory dendritic cells, the method comprising step a: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step b: identifying regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Also disclosed is a method for producing a cell population enriched for regulatory dendritic cells, the method comprising step 1: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step 2: obtaining a cell population enriched for regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Further disclosed is a cell population enriched for regulatory dendritic cells obtained by the method.

Abstract: The present invention provides a variant of a T-cell receptor containing a combination of two polypeptides containing a constant region of a T cell receptor chain selected from the group consisting of ? chain, ? chain, ? chain and ? chain, wherein the polypeptide does not contain a complementarity determining region (CDR) of the T cell receptor chain, a complementarity determining region (CDR) of the ? chain, and a complementarity determining region (CDR) of the ? chain.

Abstract: The present invention provides a method for activating/proliferating T cells, including a step of contacting a cell population containing T cells with a nucleic acid delivery carrier having at least one kind of T cell activating ligand added to its surface, and a method for delivering a nucleic acid into T cells, the methods including a step of contacting a cell population containing T cells simultaneously with (a) a nucleic acid delivery carrier having at least one kind of T cell activating ligand added to its surface and containing a nucleic acid inside, or (b) at least one kind of T cell activating ligand, and a nucleic acid delivery carrier containing a nucleic acid inside and free of a T cell activating ligand added to its surface, a method for producing a medicament containing T cells and the like.

Abstract: To enable stable supply of differentiated T cells, the present invention provides a method for producing, or a method for expansion culture, or a kit for expansion culture of a CD3-positive cell in which T cell marker CD3 is expressed on the cell membrane.

Abstract: The present invention provides a method for producing a ??T cell from an induced pluripotent stem cell, wherein the induced pluripotent stem cell is derived from a cell other than an ??T cell.

Abstract: Provided is a method for producing a CD4/CD8 double positive cell, including the following steps: step 1: separating, from a cell population containing a hematopoietic progenitor cell, a cell expressing one or more kinds of molecules selected from the first group consisting of CD24, CD62L, CD90, CD143, CD263, Notch3, CD32, CD39, CD49a, CD164, CD317, CD200, CD218a, CD7, CD144, CD56, CD226, CD262 and CD325, and/or a cell not expressing one or more kinds of molecules selected from the second group consisting of CD49f, CD51, CD102, CD42b, CD61, CD62P, CD69, CD102 and CD156c, and step 2: differentiating the cell separated in step 1 into a CD4/CD8 double positive cell.

Abstract: Provided is a T cell receptor containing, as ? chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 1 to 3, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 4 to 6, as ? chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 7 to 9, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 10 to 12, and capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 27 or a complex of the peptide and HLA-A24.